A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 25, 2019 / by / in
Comments